KR101877587B1 - 다발성 경화증(ms)의 새로운 치료 - Google Patents

다발성 경화증(ms)의 새로운 치료 Download PDF

Info

Publication number
KR101877587B1
KR101877587B1 KR1020137010891A KR20137010891A KR101877587B1 KR 101877587 B1 KR101877587 B1 KR 101877587B1 KR 1020137010891 A KR1020137010891 A KR 1020137010891A KR 20137010891 A KR20137010891 A KR 20137010891A KR 101877587 B1 KR101877587 B1 KR 101877587B1
Authority
KR
South Korea
Prior art keywords
flubiprofen
pharmaceutical composition
coo
treatment
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137010891A
Other languages
English (en)
Korean (ko)
Other versions
KR20140017494A (ko
Inventor
이름가르트 테제데
게르트 게이스링거
Original Assignee
프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 filed Critical 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우
Publication of KR20140017494A publication Critical patent/KR20140017494A/ko
Application granted granted Critical
Publication of KR101877587B1 publication Critical patent/KR101877587B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020137010891A 2010-11-03 2011-11-03 다발성 경화증(ms)의 새로운 치료 Expired - Fee Related KR101877587B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (2)

Publication Number Publication Date
KR20140017494A KR20140017494A (ko) 2014-02-11
KR101877587B1 true KR101877587B1 (ko) 2018-07-11

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137010891A Expired - Fee Related KR101877587B1 (ko) 2010-11-03 2011-11-03 다발성 경화증(ms)의 새로운 치료

Country Status (10)

Country Link
US (1) US20130309199A1 (cg-RX-API-DMAC10.html)
EP (1) EP2635271A1 (cg-RX-API-DMAC10.html)
JP (1) JP5903438B2 (cg-RX-API-DMAC10.html)
KR (1) KR101877587B1 (cg-RX-API-DMAC10.html)
CN (1) CN103209692A (cg-RX-API-DMAC10.html)
BR (1) BR112013010883A2 (cg-RX-API-DMAC10.html)
CA (1) CA2816911C (cg-RX-API-DMAC10.html)
GB (1) GB2485169A (cg-RX-API-DMAC10.html)
RU (1) RU2595861C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012059541A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
AU2018368332B2 (en) 2017-11-14 2022-05-12 Merck Sharp & Dohme Llc Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2009083115A1 (de) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2009083115A1 (de) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Roberto Furlan 등, Journal of Neuroimmunology, 2004, Vol. 150, pp. 10-19. *
Roberto Furlan 등, Journal of Neuroimmunology, 2004, Vol. 150, pp. 10-19. 1부. *
Roberto Furlan 등, Journal of Neuroimmunology, 2004, Vol. 150, pp. 10-19.*
Seok Jae Kang 등, J. Clin. Neurol., 2009, Vol. 5, pp. 146-148. *
Seok Jae Kang 등, J. Clin. Neurol., 2009, Vol. 5, pp. 146-148. 1부. *
Seok Jae Kang 등, J. Clin. Neurol., 2009, Vol. 5, pp. 146-148.*

Also Published As

Publication number Publication date
JP2014505015A (ja) 2014-02-27
RU2013125470A (ru) 2014-12-10
RU2595861C2 (ru) 2016-08-27
GB201018519D0 (en) 2010-12-15
CA2816911C (en) 2018-09-25
US20130309199A1 (en) 2013-11-21
KR20140017494A (ko) 2014-02-11
GB2485169A (en) 2012-05-09
CA2816911A1 (en) 2012-05-10
WO2012059541A1 (en) 2012-05-10
CN103209692A (zh) 2013-07-17
EP2635271A1 (en) 2013-09-11
BR112013010883A2 (pt) 2016-09-13
JP5903438B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
US11690832B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US10966962B2 (en) Method for treating neurodegenerative diseases
RU2595861C2 (ru) Новое лечение рассеянного склероза ( рс )
JP6038653B2 (ja) 低頻度酢酸グラチラマー治療
AU2014204737A1 (en) Solid solution compositions and use in severe pain
WO2010147484A1 (en) Compositions and methods for treatment of multiple sclerosis
JP6450814B2 (ja) 医薬組成物及びその用途
KR20220109378A (ko) 병용 요법 방법, 조성물 및 키트
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
US20200246357A1 (en) Use of Nor-Ursodeoxycholic Acid for Reducing Liver Fat
IT202100014333A1 (it) Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2)
US11690834B2 (en) Composition, uses, and methods of treating spinal disc degeneration through sonic hedgehog signaling pathway
JPWO2020054872A1 (ja) 急性帯状疱疹痛の治療剤
JPWO2010047295A1 (ja) 帯状疱疹関連痛の予防又は治療薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220706

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220706

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000